{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744+Tablets&page=2",
    "query": {
      "intervention": "GSK1265744 Tablets",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1265744+Tablets&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T06:18:14.434Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02178800",
      "title": "Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK1265744 Tablets",
          "type": "DRUG"
        },
        {
          "name": "Injectable GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "Placebo for GSK1265744 Tablets",
          "type": "DRUG"
        },
        {
          "name": "Injectable Placebo for GSK1265744",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 199,
      "start_date": "2015-02",
      "completion_date": "2018-07-13",
      "has_results": true,
      "last_update_posted_date": "2021-10-18",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02178800"
    },
    {
      "nct_id": "NCT04001803",
      "title": "Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB LA+RPV LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-07-08",
      "completion_date": "2022-03-18",
      "has_results": true,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04001803"
    },
    {
      "nct_id": "NCT07473778",
      "title": "Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Lenacapavir Injection",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine/tenofovir disoproxil fumarate (F/TDF)",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine/tenofovir alafenamide (F/TAF)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir (CAB)",
          "type": "DRUG"
        },
        {
          "name": "Lenacapavir Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3000,
      "start_date": "2026-03-17",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07473778"
    },
    {
      "nct_id": "NCT03739996",
      "title": "Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Oral Cabotegravir (CAB)",
          "type": "DRUG"
        },
        {
          "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)",
          "type": "DRUG"
        },
        {
          "name": "Long-Acting Injectable Cabotegravir (CAB LA)",
          "type": "DRUG"
        },
        {
          "name": "VRC07-523LS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of Care (SOC) ART",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2019-12-31",
      "completion_date": "2024-04-29",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03739996"
    },
    {
      "nct_id": "NCT05660980",
      "title": "Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Once daily CAB tablet + RPV tablet",
          "type": "DRUG"
        },
        {
          "name": "Long acting CAB injectable + long acting RPV injectable",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 90,
      "start_date": "2024-01-24",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Memphis, Tennessee",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660980"
    },
    {
      "nct_id": "NCT02076178",
      "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "744 Tablet",
          "type": "DRUG"
        },
        {
          "name": "744 LA Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2014-03-27",
      "completion_date": "2016-02-23",
      "has_results": true,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076178"
    },
    {
      "nct_id": "NCT02354950",
      "title": "A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK1265744 30mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-06-22",
      "completion_date": "2016-09-16",
      "has_results": false,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 3,
      "location_summary": "Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02354950"
    },
    {
      "nct_id": "NCT05374525",
      "title": "A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "APRETUDE",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir OLI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 287,
      "start_date": "2022-05-18",
      "completion_date": "2024-08-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374525"
    },
    {
      "nct_id": "NCT04371380",
      "title": "Pharmacokinetic Study of Cabotegravir and Rilpivirine Long-acting Intramuscular Injections in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Tablets",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine Tablets",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir extended release suspension for injection (long-acting)",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine extended release suspension for injection (long-acting)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-09-16",
      "completion_date": "2021-12-26",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04371380"
    },
    {
      "nct_id": "NCT02027454",
      "title": "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK1265744",
          "type": "DRUG"
        },
        {
          "name": "GSK1265744 matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-16",
      "last_synced_at": "2026-09-27T06:18:14.434Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027454"
    }
  ]
}